A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC
| Condition | Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer, Non-Small-Cell Lung Carcinoma |
|---|---|
| Phase | Phase 2 |
| Sponsor | Joseph J. Cullen, MD, FACS |
| Status | Active, not recruiting |
| Enrollment | 43 participants |
| Interventions | Radiation Therapy, Paclitaxel, Carboplatin, Ascorbic Acid |
| Start date | Nov 16, 2018 |
| Completion date | Jul 15, 2025 |
| Results posted | Jul 31, 2026 |
Summary
This clinical trial evaluates adding high-dose ascorbate (vitamin C) to a standard therapy for non-small cell lung cancer. The standard therapy is radiation therapy combined with carboplatin and paclitaxel (types of chemotherapy). All subjects will receive high-dose ascorbate in addition to the standard therapy.
Progression Rate at the Completion of Radiation and Chemotherapy
| ChemoRT + Ascorbate | 6 Participants |
|---|
Open in BENITIONS View on ClinicalTrials.gov
Other trials for this condition
- A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients W — AstraZeneca
- Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With — National Cancer Institute (NCI)
- Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Pos — National Cancer Institute (NCI)
- Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage I — National Cancer Institute (NCI)
- Premedication to Reduce Amivantamab Associated Infusion Related Reactions — Janssen Research & Development, LLC
- A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab — Janssen Research & Development, LLC